• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-K filed by Repligen Corporation

    3/13/25 7:14:28 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGEN alert in real time by email

    Unavailable

    Get the next $RGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGEN

    DatePrice TargetRatingAnalyst
    6/24/2025$150.00Overweight
    Barclays
    4/29/2025$160.00Peer Perform → Outperform
    Wolfe Research
    3/18/2025$155.00In-line
    Evercore ISI
    2/10/2025$200.00Buy
    TD Cowen
    12/17/2024$165.00Hold
    Canaccord Genuity
    11/14/2024Peer Perform
    Wolfe Research
    8/28/2024$180.00Overweight
    Wells Fargo
    6/26/2024$180.00 → $155.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $RGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials
    • Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

      WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed "Perspectives on Progress", this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2024 Corporate Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and two

      5/27/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Corporation to Present at William Blair Growth Conference

      WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen CorporationRepligen Corporation is a global

      5/22/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care